Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | SVP, Chief Scientific Officer | October 25, 2016 | January 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date October 25, 2016 · Filed January 19, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Tapscott-Eliasof 2012 Family Trust | 100 |
Reported balance
Holding disclosure · report date 2016-10-25 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 100 F1: These shares were omitted from the reporting person's original Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were omitted from the reporting person's original Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2017 Filed Jan 9, 2017 17:12 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002976 · doc4.xml · derivative · entry 2 Eliasof Scott · CIK 0001688065 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:12 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002976 · doc4.xml · derivative · entry 1 Eliasof Scott · CIK 0001688065 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 16:28 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-16-147150 · doc4.xml · derivative · entry 1 Eliasof Scott · CIK 0001688065 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-24 F1 · derivative.exercise_date: This option was granted on October 25, 2016. The shares underlying the option are subject to vest in equal monthly installments over four years from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.